Insider Selling: Pharvaris (NASDAQ:PHVS) Director Sells 7,000 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 7,000 shares of Pharvaris stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $30.05, for a total value of $210,350.00. Following the transaction, the director directly owned 388,167 shares of the company’s stock, valued at approximately $11,664,418.35. This represents a 1.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total value of $3,003.00.

Pharvaris Stock Performance

PHVS stock traded up $1.25 during midday trading on Friday, hitting $28.54. 129,619 shares of the stock were exchanged, compared to its average volume of 172,220. The stock’s 50-day moving average price is $27.39 and its 200-day moving average price is $25.80. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -8.47 and a beta of -2.58. Pharvaris N.V. has a fifty-two week low of $14.59 and a fifty-two week high of $30.24.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Friday, April 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.15). Research analysts anticipate that Pharvaris N.V. will post -3.19 EPS for the current year.

Institutional Investors Weigh In On Pharvaris

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. General Atlantic L.P. grew its position in shares of Pharvaris by 6.6% in the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after purchasing an additional 500,000 shares during the period. Foresite Capital Management IV LLC grew its position in Pharvaris by 8.3% during the third quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after acquiring an additional 368,000 shares during the period. venBio Partners LLC grew its position in Pharvaris by 8.2% during the third quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after acquiring an additional 350,000 shares during the period. Deerfield Management Company L.P. grew its position in Pharvaris by 21.1% during the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock valued at $60,939,000 after acquiring an additional 425,000 shares during the period. Finally, Commodore Capital LP grew its position in Pharvaris by 26.5% during the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after acquiring an additional 507,043 shares during the period.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PHVS. Wolfe Research began coverage on Pharvaris in a report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday. Citigroup reissued a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Royal Bank Of Canada cut their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday, April 6th. Finally, Wedbush boosted their price target on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $42.73.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.